As the drug development industry evolves, PPD is seeing a significant shift to outsourcing, specifically toward the use of functional service partnerships (FSPs). In this report, experts at PPD weigh in on questions surrounding: 

• Key industry challenges that have contributed to this shift to outsourcing 
• FSP market size and percentage of outsourcing observed 
• Ranked benefits of working with an FSP model

With these insights, drug developers will better understand what’s driving the shift to FSP services and why they should consider FSP as an outsourcing model.